Thank you, and good morning. Welcome to MediLife's earnings conference call to discuss our Q2 2021 financial and operating results. We are conducting this call virtually. The earnings release, financial statements and within MD and A, statistical information package and webcast slides for today's call are available on the Investor Relations section of our website at manulife.com. Turning to Slide 4, we will begin today's presentation with an overview of our Q2 highlights and an update on our strategic priorities by Roy Gory, our President and Chief Executive Officer.
Following Roy's remarks, Phil Worthington, our Chief Financial Officer, will discuss the company's financial and operating results. After the prepared remarks, which were recorded in advance to ensure optimal sound quality, we will move to the live question and answer portion of the call. We ask each participant to adhere to a limit of 2 questions. If you have additional questions, please re queue and we will do our best to respond to all questions. Before we start, please refer to Slide 2 for a caution on forward looking statements and Slide 32 for a note on the use of non GAAP financial measures in this presentation.
Note that certain material factors or assumptions are applied in making forward looking statements and actual results may differ materially from what is stated. With that, I'd like to turn the call over to Roy Gory, our President and Chief Executive Officer. Roy?
Thanks, Hung. Good morning, everyone, and thank you for joining us today. Yesterday, we announced our financial results for Q2 of 2021 and our strong momentum continued from the start of the year with double digit growth across a number of our key operating metrics compared with the prior year quarter. Turning to Slide 6, we delivered record core earnings of $1,700,000,000 an 18% increase from the prior year with double digit growth across our growth engines, Asia and Global WAM. And we reported net income of $2,600,000,000 New business value increased 57% with strong contributions across all geographies, reflecting higher sales volume and more favorable margins.
Our expense efficiency ratio improved by 2.1 percentage points compared with the prior year, demonstrating our continued focus on expense management. In our Global WAN business, we continue to build scale and benefited from growth in higher margin businesses. As a result, our core EBITDA margin increased 4.40 basis points from the prior year. Our MBV margin for Asia increased by 3.6 percentage points from the prior year, and this represents a tremendous growth from 5 years ago when the margin was in the low 30s. Turning to Slide 7 and the progress that we've made executing on our 5 priorities.
As we discussed at our Investor Day in June, the next phase of our strategy is focused on accelerating growth and becoming the most digital customer centric global company in our industry. I'm very pleased with our progress in these areas. Growth in our highest potential businesses has outpaced other areas since 2019, and that continued in the 2nd quarter with both Asia and Global WAM delivering double digit growth in core earnings. Our highest potential businesses accounted for 61% of total company core earnings year to date 2021. And we're on track to achieve our target of 67% of total company core earnings by 2022.
In Asia, we announced the 3 year partnership with Glimmera, a leading global trade association for the financial services industry in order to further recruit best in class agents across Asia. This partnership complements our newly launched Manulife Business Academy, our region wide unified learning and development platform for our growing number of agents. Global WAN's managed AUMA totaled more than $1,000,000,000,000 reflecting our track record of positive net flows and strong investment performance. And we secured an alternative investment fund manager's license to offer onshore private market funds in our key European markets. This is a major milestone in driving the expansion and offering of our private market investment capabilities within Europe.
On the behavioral insurance front, we launched the Manulife Vitality Healthy Mine Reward Program to help our individual insurance customers improve their mental and emotional well-being. Our ambition is to be a leader in our industry when it comes to digital capabilities and customer experience. And we're executing on our strategy to attract, engage and retain customers by delivering an outstanding experience. There is strong evidence that higher NPS results in increased customer retention, higher number of products per customer, increased investment balances and higher referrals, leading to lower acquisition costs and agent recruiting costs. Since 2018, we've invested $750,000,000 in digital enhancements, which have positioned us well to better engage with our customers and has contributed to our NPS of plus 19 as of the Q2 of 2021.
This is an 18 point improvement from our 2017 baseline and we're on track to achieve our NPS target of +31 by 2022. During the Q2, we continue to make progress on our digital journey across all our operating segments to better engage with our customers. In Asia, we entered into a new digital collaboration with Rewards, a rewards aggregator and management solution to further incentivize customers that are part of our move program to be physically active. In the U. S, we continue to enhance our digital underwriting capabilities by integrating our underwriting decision engine with iPipeline, A leading provider of no code or low code content based digital solutions to accelerate the life insurance application process.
This new approach will dramatically reduce the life insurance sales cycle and offer a less intrusive way to collect medical history data with digital signatures. In our Global WAM business, we launched a new retirement mobile app for all U. S. Plan members. The new app gives members the ability to enroll in their plan, view account details, make changes to their account and use additional financial tools to provide them with guidance on their retirement savings strategies and financial priorities.
Turning to Slide 8, Expense efficiency is deeply embedded in our culture and I'm pleased to see the benefits reflected in our 2nd quarter expense efficiency ratio of 46.8%. The ratio improved by 2.1 percentage points year over year, reflecting Pre tax core earnings growth of 16% that far outpaced core expense growth of 5%. We've made significant progress towards meeting our goal of consistently achieving a ratio of less than 50%. In the Q2, we freed up $200,000,000 of capital, primarily driven by our annuity guaranteed minimum withdrawal benefit offer program in the U. S.
The GMWB Offer program has reduced the guaranteed value of the USDA business by approximately 7% since it was launched in 2019. It's a prime example of our organic initiatives to optimize capital and reduce risk. On a cumulative basis, we've freed up $6,100,000,000 of capital through our portfolio optimization efforts across multiple legacy blocks. Whilst we've exceeded our target of releasing $5,000,000,000 of capital, Our commitment to optimize Manulife's legacy portfolio, especially LTC and VA remains and we continue to seek opportunities to reduce risk and unlock value. As I announced at Investor Day, we plan to reduce the core earnings contributions from LTC and VA to less than 15% of total company core earnings by 2025.
And I look forward to providing you with an update on our progress towards all of our 2025 supplemental goals at year end. Our final priority is around building a high performing team. I believe that culture will be a sustainable long term competitive advantage and that only a highly engaged high performing team can consistently exceed customer expectations and deliver superior results. Our target is to achieve top quartile employee engagement compared to Global Financial Services and Insurance peers by 2022. And we are proud to have achieved this ranking in 2020.
We continue to deliver against our goals of increasing women in our leadership ranks. And our new graduate hiring of black indigenous and people of color talent In 2020, reached 52%, more than doubling our goal. In addition, we're continuing to develop our high performing team and winning culture through initiatives focused on well-being, learning and recognition. Highlights include our 2nd annual global thank you day for all colleagues, as well as our bespoke elevate well-being program. Our global initiative to encourage and help our teams focus on their well-being.
And we're on the path to building a culture of sustainability to better our planet. In May, we announced our commitment to net zero emissions to support climate goals worldwide, recognizing the important role that 37,000 employees, 118,000 agents and over $1,000,000,000,000 in AUMA can play in Global Climate Solutions. Of note, I'm proud to share that we're already net 0 in our operations due to the carbon removals from our substantial owned and operated forest and farmland.
Our journey
to net 0 focuses on 3 key areas. Through our operations, we will substantially reduce emissions to lessen our footprint. We'll actively invest for
a sustainable future
With our products and services, we'll develop innovative solutions that contribute to climate change mitigation and resilience. To conclude, we continue to demonstrate great progress against our strategic priorities. We're executing on the next phase of our strategy with a greater focus on accelerating growth in our highest potential businesses. Our strong results in the Q2 of 2021 showcase the strength of our Asia and Global WAN businesses, and I'm pleased with our progress towards delivering on our goals. Our commitment to continue to optimize our legacy businesses, especially LTC and VA is as strong as ever.
We continue to invest in our digital capabilities to both improve customer experience and deliver on our efficiency target. While the challenging and uneven operating environment continues across many markets globally, we're pleased to see a path to reopening in many of the world's largest economies. We continue to believe that Manulife is uniquely positioned to win as the global economy positions the recovery and are optimistic about the future of our franchise. Thank you. And I'll hand over to Phil Witherington, who will review the highlights of our financial results.
Phil?
Thank you, Roy, and good morning, everyone. Turning to Slide 11 and our financial performance for the Q2 of 2021. As Roy mentioned, our strong momentum continued in the 2nd quarter. We delivered double digit growth in Asia and Global WAM, resulting in record core earnings of $1,700,000,000 and total company net income of $2,600,000,000 Strong customer demand combined with favorable market sentiment during the quarter contributed to double digit APE sales and new business value growth across all insurance segments as well as an increase in net flows and average AUMA in our global WAM business And our LICAT ratio of 137% and leverage ratio of 25.9% provide us with financial flexibility to deliver on our strategic priorities. We will complete our annual review of actuarial methods and assumptions during the Q3 of 2021.
And while this review is not yet complete, preliminary indications suggest the impact will be roughly neutral. Separately, in June 2021, the Canadian Actuarial Standards Board issued new guidance with reductions to the ultimate reinvestment rate and updates to the calibration criteria for stochastic risk free rates. These updated standards include a reduction of 15 basis points in the URR and a corresponding change to the stochastic risk free rate modeling and will be effective from October 15, 2021. We expect to adopt this standard in the Q3 of 2021 and consistent with our disclosed sensitivities, we estimate that it will reduce net income attributed to shareholders by approximately $550,000,000 post tax. The impact of this change will be reported in items excluded from core earnings as part of the direct impact of markets.
I will highlight the key drivers of our 2nd quarter performance with reference to the next few slides. Turning to Slide 12. We generated core earnings of $1,700,000,000 in the higher new business gains across all insurance segments, higher net fee income from higher average AUMA in our global WAN business, the recognition of core investment gains in the quarter and in force business growth in Asia and Canada. These items were partially offset by modestly unfavorable net policyholder experience compared with net favorable COVID-nineteen impacts in the prior year quarter and lower net gains on seed money investments in segregated and mutual funds. Net income attributed to shareholders was $2,600,000,000 in the 2nd quarter, reflecting growth in core earnings, gains from investment related experience compared with losses in the prior year quarter and larger gains from the direct impact of equity markets and interest rates.
Of note, we delivered investment related experience gains of $839,000,000 in the quarter, reflecting higher than expected returns on Alder, primarily driven by fair value gains on private equity, the favorable impact of fixed income reinvestment activities and favorable credit experience. $100,000,000 of these investment related experience gains were reported in core earnings with the remaining $739,000,000 reported outside of core earnings. The direct impact of markets in the quarter was a gain of $177,000,000 reflecting strong equity market performance. The gain of $40,000,000 from the direct impact of interest rates which is the result of lower risk free rates and flattening of the yield curve, partially offset by a charge from the sale of AFS bonds. Our year to date 2021 net income attributed to shareholders of $3,400,000,000 was above core earnings of $3,300,000,000 despite market volatility throughout the year.
This reflects the transitory nature of market impacts on our income period over period and our ability to manage market risks effectively over time. Slide 13 shows our source of earnings analysis. Expected profit on in force increased by 8% on a constant exchange rate basis, driven by growth in Hong Kong, Japan, Vietnam and Canada Group Insurance. New business nearly doubled compared with the prior year quarter with growth across all insurance segments driven by Higher sales, improved margins and a more favorable product mix in the U. S.
Favorable product mix and strong sales in Hong Kong as well as Asia Other and higher sales in Canada Retail Insurance. Net policyholder experience in the Q2 was modestly unfavorable, primarily driven by adverse claims experience in U. S. Life, partially offset by favorable claims experience in Canada Group Insurance. Long term care policyholder experience was approximately neutral.
Core earnings on surplus decreased compared with the prior year quarter, largely due to the net impact of lower yields on fixed income investments and lower net gains on seed money investments in segregated funds and mutual funds, partially offset by gains on the sale of AFS Equities. Turning to Slide 14. We delivered core earnings growth of 62% in our global WAM business, reflecting growth in net fee income driven by higher average AUMA from the favorable impact of markets and net inflows as well as favorable business mix. Core earnings in Asia increased by 20% driven by higher new business volumes, reflecting a lessening of the impact of COVID-nineteen on sales, favorable product mix and in force business growth, partially offset by modestly unfavorable policyholder experience and lower investment income on allocated capital. Core earnings in Canada decreased by 7%, primarily driven by a lower level of favorable policyholder experience compared with the impact of COVID-nineteen containment measures on claims in the prior year quarter and lower investment income on allocated capital, partially offset by higher in force earnings and higher sales in our retail insurance business.
Core earnings in the U. S. Decreased by 10%, primarily driven by a less favorable impact from COVID-nineteen on long term care policyholder experience and lower investment income on allocated capital, partially offset by higher new business volumes. Core losses in Corporate and Other improved by $114,000,000 primarily driven by core investment gains, partially offset by the net impact of lower yields on fixed income investments, lower net gains on seed money investments in segregated funds and mutual funds, gains on sales of AFS Equities and lower interest on allocated capital to operating segments. Slide 15 shows our new business value generation and APE sales.
Our insurance business delivered very strong new business Value of $550,000,000 in the Q2 of 2021, an increase of 57% versus the prior year quarter with double digit growth across all insurance segments. In Asia, NBV increased 48% from the prior year quarter, driven by higher sales volumes in Asia Other Markets, favorable interest rates, higher sales volumes and product management actions in Hong Kong and expense management actions and favorable product mix in Japan due to a shift away from lower margin COLI products. In Canada, NBV increased 65% from the prior year quarter due to the impact of higher sales volumes and more favorable margins. In the U. S, NBV doubled the level of the prior year quarter, primarily driven by higher sales volumes and more favorable margins.
In the Q2 of 2021, We delivered APE sales of $1,400,000,000 a 30% increase from the prior year quarter. While COVID-nineteen impacts on sales have moderated, the pandemic continued to have varying degrees of adverse impacts across the markets in which we operate. In Asia, APE sales increased by 34%, reflecting double digit growth in both Bancassurance Agency channels in Asia Other Markets and Hong Kong, which benefited from continued strong domestic demand and emerging demand from Mainland Chinese visitors, partially offset by lower COLI product sales in Japan. In Canada, APE sales increased by 16%, primarily driven by higher sales of lower risk segregated fund products, higher retail insurance sales and higher small and midsized group insurance sales, partially offset by the non recurrence of a large affinity market sale in the prior year and lower large case group insurance sales. In the U.
S, APE sales increased by 40% due to higher customer demand across all product lines. APE sales of products with the John Hancock Vitality Plus feature increased by 27% as the feature continues to be a differentiator in the market. Turning to Slide 16. Our Global Wealth and Asset Management business delivered net inflows of $8,600,000,000 with gross flows of nearly $34,000,000,000 during the Q2 and also benefited from the favorable impact of markets. In retail, net inflows were $7,300,000,000 compared with net outflows of $1,000,000,000 in the prior year quarter.
The increase was driven by double digit growth in gross flows across all geographies and lower mutual fund redemptions in the U. S. Institutional Asset Management net inflows were $1,900,000,000 compared with net inflows of $6,500,000,000 in the prior year quarter. The year over year change was driven by Canada from the non recurrence of a $6,900,000,000 sale in the prior year and a $1,000,000,000 sale to an existing client in the Q2 of 2021. In Retirement, net outflows were $600,000,000 compared with net outflows of $300,000,000 in the prior year quarter, reflecting higher member withdrawals, partially offset by growth in new planned sales and member contributions.
Overall, Global WAM's average AUMA increased by 26% compared with the prior year quarter, driven by the favorable impact of markets and higher net inflows. As part of the expanded disclosures introduced at our recent Investor Day, I'm pleased to highlight the net fee income yield metric. Global WAM's net fee income yield of 44.4 basis points increased by 0.8 basis points from the prior year quarter, reflecting favorable business mix, which benefited from growth in retail net inflows. And Core EBITDA margin increased by 4.40 basis points, driven by a combination of higher net fee income, operational benefits from increased scale and disciplined expense management. The strong growth in average AUMA and core EBITDA margin Turning to Slide 17.
Our strategic expense management program is mature and efficiency is embedded in our culture. We delivered an expense efficiency ratio of 46.8 percent in the Q2 of 2021 with an improvement of 2.1 percentage points compared with the prior year quarter. This improvement was driven by a 16% increase in pretax core earnings, which far outpaced the 5% increase in general expenses included in core earnings. We remain committed to our goal of consistently achieving a ratio of less than 50%. As I mentioned at our recent Investor Day, we set our sights on achieving positive jaws in 2023 and beyond, meaning that we will endeavor to have our top line growth, The denominator of our efficiency ratio exceed our core general expenses growth rate.
Turning to Slide 18. We continue to maintain a strong balance sheet and capital position. We have $23,000,000,000 of capital above the supervisory target, and our LICAT ratio of 137% is strong. The ratio is in line with the prior quarter as favorable impacts from market movements, mainly from lower risk free rates and older gains, were offset by the impact of capital redemptions of $2,100,000,000 Our financial leverage decreased 3.6 percentage points from the prior quarter to 25.9 percent, driven by the redemption of debt and Capital instruments of $2,100,000,000 growth in retained earnings and the favorable impact of lower interest rates on the value of AFS debt Securities partially offset by the unfavorable impact of a stronger Canadian dollar. We remain committed to achieving our 25% medium term leverage target, but would note that the ratio is subject to variation period over period due to the timing of financing activities.
Slide 19 outlines our medium term financial targets and recent performance. Core ROE and the expense efficiency ratio met our medium term targets in the Q2 of 2021, and our dividend payout ratio remains within our target range. We remain confident in delivering 10% to 12% core EPS growth over the medium term. Of note, core EPS growth of 6% in the Q2 of 2021 reflects the impact of currency translation. On a constant exchange rate basis, Q2 2021 core EPS grew 17% compared with the prior year quarter.
This concludes our prepared remarks. Operator, we will now open the call to questions.
Thank you. We will now take questions from the telephone lines. The first question is from Humphrey Lee of Doolin Partners. Your line is open. Please go ahead.
Good morning and thank
you for taking my questions. My first question is related to new business gains in Asia. While it showed a good year over year growth, but It's a little bit softer compared to the LIFO's we have seen over the past several quarters. I believe the sales mix had an impact on that. But I was just wondering if you can elaborate on some of the moving pieces from new business gains that we've seen in the quarter and what is your outlook for that coming from Asia in the coming quarters.
Thanks, Humphrey. Thanks for the question. This is Anil. So As you rightly pointed out, our growth of new business gain in quarter 2 has been very strong. We are very pleased with the 51 Growth that we've seen year on year on a constant exchange rate basis and that's on account of a few factors.
1, It's been aided on account of the strong new business sales and we illustrated during the Investor Day as well that We continue to expand our distribution, continue to improve our digital and technology capabilities as well as upscale and upgrade Our talent. And we were very well positioned as we entered 2021, started the year strongly and then kind of back it up with a strong quarter 2 performance as well. In addition to that, we have been taking a number of steps on driving product mix. We have taken a number of re pricing actions over the last 12 to 18 months as well as you would have heard Phil illustrate, Been very disciplined around our expenses. So a combination of these factors have resulted into the growth that you're witnessing on the new business Gain line.
The new business growth, we believe, is quite consistent with our sales volume. So As you reckon, it is highly correlated with new business sales. And if you look at the correlation, it's quite consistent over quarter 1 and quarter 2. And to your second question in terms of the outlook, If I were to kind of draw your attention to the trajectory of the previous three quarters and if you were to kind of normalize that for The seasonality of quarter 1, which as you know is primarily the China door opening effect, That will give you a good indication, Humphrey, of the new business gain trajectory. I would also like to point out, in addition to that, That we've also witnessed a 16% growth on EPIF and that is our ongoing focus on Driving value out of our in force book.
The only thing I would caveat in terms of outlook is that we have seen more recently resurgence of COVID in many of our Southeast Asian markets. And while we have had a significant experience over the last 18 months to operate in a COVID environment, obviously, that's something that we are watching Seatingly closely. As you reckon, the containment measures that get enforced from time to time across markets do have an impact on the mobility of our distributors and customers that could present a challenge on momentum In the short term, but we remain very confident about our medium to long term targets that we had recently shared with you during the Investor Day. Thanks for the question once again Humphrey.
That's helpful. But I guess looking back at the past several quarters, It's probably around $170,000,000 of new business gains in quarter 3 and quarter 4. And then obviously, Q1 was very strong because of the door opening in Got it. And then this quarter is kind of around $160,000,000 So it seems a little bit lighter than like I guess The second half of last year where your APE sales were kind of comparable, like just how to think about that change?
Yes. So I think as I pointed out, I
think from a year on year perspective, our growth has been pretty solid as you would have seen From our disclosures, I guess, you will always have some level of variability depending upon the geographic mix As well as product mix as you highlighted in your question. But as I said, the correlation between New business sales and new business gain, in our reckoning has been pretty consistent. As I said, If you do normalize for quarter 1 seasonality, it should kind of give you a good indication of our new business gain estimate.
I'll just add,
I think Anil covered
it quite well, but I would just say that seasonality It isn't just affecting necessarily our total sales, it will also affect the sales by geography. And as you highlight, Q3, Q4 isn't Radically off what you saw in Q2 from a results perspective, but the makeup of our results does vary based on seasonality. It's obviously more pronounced with Q1 in China. But there is a bit of a mix across the different markets. And Q2 isn't radically different Q3, Q4 as you highlighted, I wouldn't look at that as a big difference.
And again, it really goes to the 4 of the geographic diversity that's really Very helpful for us and has allowed us to continue to deliver strong results and quite frankly gain market share across many markets in Asia, not only in 20 But in 2021 as well.
Thank you. Appreciate that. My second question is related to Global WAM. You saw very strong retail net flows in the quarter and as you pointed out strong gross sales across geographies and low redemption. Can you just talk about where you're seeing traction in terms of kind of which geography is getting stronger inflows and then also what type of asset classes Again, the inflows?
Yes. Thanks, Humphrey. It's Paul here and I'll answer the question. Yes. As you mentioned, we had a very strong quarter this quarter in terms of gross flows and net flows.
And retail was the primary driver there. And Phil mentioned in As opening remarks, we did see double digit growth across all three regions in growth flows. I think that just speaks to just the underlying quality of the Franchise and the diversification. It's also worth noting that in our U. S, it was the 4th straight consecutive quarter of positive net Close in our U.
S. Business, that's also contributing here. We've seen continued momentum in that business building off the last three quarters. The other thing helping us here is in terms of your question on mix. If you look back to maybe the start of 2020, we were selling quite a bit of fixed income.
We were seeing a much more balanced mix of sales now, particularly within the retail channel to equity and to balance mandates. So that's also helping Drive the overall flows and profile of the business, but also support that net yield that we're now Closing. So we're just the fundamentals of the business are very strong. And I would say they're also strong in the other channels as well, just not as pronounced as retail where we're seeing a big impact.
Got it. Thank you.
Thank you. The next question is from Tom MacKinnon of BMO Capital Markets. Please go ahead.
Yes, thanks very much. Good morning. Want to talk a little bit about the policyholder experience losses in the quarter. And if we look at Overall, the experienced gains and losses on a core basis were 34 It seemed to be in line with what we were looking for despite probably higher policyholder experience losses. So Maybe you can kind of explain what other experienced gains or losses might have been in there.
So I guess to summarize, it would just be a little bit more color on the policyholder experience losses by geography and What were the other core experienced gains or losses that contributed to the minus 34 that you reported. Thanks.
Thanks, Tom. It's Steve here and I'll be happy to answer that question. As Phil noted, our overall policyholder experience was slightly unfavorable at $15,000,000 loss. And the big the drivers there that Phil called out, U. S.
Life claims experience. The one piece of color I'd add there Is the bulk of what we saw in terms of coming through as a loss occurred at the start of the quarter in April? I think we're seeing Some COVID trends in those results, but it got better over the course of the quarter. Those were offset by gains in our Canadian Group Insurance Business, primarily in our long term disability business where we saw strong recoveries. And then Asia was close to neutral, some modest claims gains and Some lapse losses that were across a number of geographies not concentrated in any one area.
And then in terms of what else goes into core experience, What goes in there as well is our expense related experience and reminder that that includes our regional overhead costs In Asia. And then what we see is we do see some variability in that line from reinsurance related items And we had some a number of small positives there in this quarter. So those are the key drivers of what we're seeing in the Policyholder experience and the core experience line.
Okay. And What about did you mention long term care? How was that was neutral in the quarter? Is there any and I think you mentioned That there's been a sort of a COVID impact that's been progressing from April And I guess improving maybe in your U. S.
Life, maybe you can shed how that sort of COVID impact has impacted long term care and what you would expect going forward with respect to long term care experience?
Sure. In Long Term Care, what we saw in the quarter, it was a small positive result, close Too neutral, but small positive. And for context, remind people that the vaccination effort in the U. S. For The population over 65, the vaccination program has been very successful with 80% of that population fully vaccinated and 90% with at least one dose.
So How that's translating? We saw in long term care, a reversion back towards more normal trends. We had reported in the past that we had seen customers suspending care and not seeking care. And we provided Thank you for that in our IBNR. What we saw this quarter is that we saw a greater trend to resumption of care where care had stopped And we saw a trend to more normal initiation of care.
And then in terms of the impact on Claim terminations, we saw that because of those vaccine efforts, the rate of claim termination, so deaths Of our insureds on claim that came back down more towards more normal levels as well. And while it's difficult To predict exactly how this plays out over the course of the year, our expectation is that we will continue to see a trend back to more normal experience.
Okay. And any update on the U. S. Variable annuity legacy transaction that you flagged at your Investor Day?
Hi, Tom. It's Naveed here. What I can say is that it's certainly a robust market for VA. There's lots of buyers with interest in variable annuities in the U. S.
We are continuing discussions and engaging with prospective buyers and we continue to believe that a deal is possible in 2021.
Okay. Thank you.
Thank you. The next question is from Doug Young of Desjardins Capital Markets. Please go ahead.
Hi, good morning. I guess it's back to Aneel on Asia and specifically on new business value margins. Just hoping to get some color. On one side, we did see a decline of 4.3 points in other Asia. And on the flip side, we did see Hong Kong new business Emergent 75.8 percent, I think that's the highest I can recall.
And so just trying to get a sense, is there some unusual items here? What's really kind of Flexing these two margins in different directions.
Thanks for the question. And let me start with Hong Hong Kong first. So the Hong Kong new business value was driven on account of a few reasons. 1, We saw a growth of 7% on sales. But importantly, we have been focusing On driving value across all our geographies and obviously Hong Kong being our flagship and scale business, It's most evident in terms of the scale as well as some of the initiatives that we are driving in our Hong Kong market.
Clearly, product mix has been a key driver of it. It's been aided by some of the repricing actions that we've Taken in Hong Kong now for multiple quarters as well as despite the growth that we witnessed in Hong Kong now for Multiple years, we have been exceedingly disciplined about our expenses. So a combination of that has And have resulted into the strong growth that we witnessed on the new business value margin in Hong Kong. With respect to Asia Other and again, I do want to kind of highlight the fact that Asia Other continues Performed exceedingly strongly. The new business value growth year on year stood at 59%.
And again, that should not surprise us Given the constitution of Asia Other, we have markets like China, Singapore, Indonesia, Vietnam That kind of constitute Asia Other. So it not only provides diversification strength to Asia, but also provides diversification strength To the Asia Other segment. The new business value margin largely from a year on year basis On a quarter on quarter basis, has been impacted on account of, again, some of the market mix or the geographic mix that we witnessed that could change from quarter on quarter as well as some of the product mix that could drive The new impact on new business value margin. But suffice to say, just kind of given the diversity strength as well as our Significant market position in many of our geographies in Asia and other combined with the under penetration that exist in many of these markets, We believe that we are very well positioned to be able to capture the growth opportunity in the Asia Other segment.
And just a follow-up on
the Hong Kong, is that it sounds like you think that 75% is sustainable given I mean, there's going to be seasonality obviously, but You feel that's sustainable
level? Yes. We believe, as I said, it's also represented Representation of the fact that Hong Kong is our flagship business and a scaled operation. We have been gaining Market share now for multiple quarters in Hong Kong. And again, quarter 1 of this year has been No exception.
Hong Kong, however, does tend to be a little bit sensitive to interest rates. So that's something that We will have to take in account quarter on quarter. But again, I think what we are focused on are the core drivers of what drives NBV. And that is, as I said, higher volume product mix as well as some of the repricing actions combined with our expense So we feel good about the opportunity in Hong Kong. And again, the scale nature of Hong Kong Should be able to help us deliver the growth at very healthy margins going forward.
Okay. And just second, in Japan, there was a 5% quarter over quarter Drop in agents, I think you talked a bit about repositioning that business following the shift with COLI. And is this just part of normal turnover? Or was there some Colleen, or was there something a little bit more deliberate in what you're doing in Japan?
Yes. I think we have been emphasizing in Japan In light of some of the changes that we are witnessing in the COLI market, our emphasis as we have mentioned on previous This call has been in terms of driving in force as well as expense efficiency. And the number of Initiatives that we have taken on both these accounts have resulted into positive attribution, Both on core earnings in Japan that grew at 8% year on year as well as new business value that grew by 13% Year on year. We would, as I said, see some level of fluctuation quarter on quarter From an agent headcount growth. But as I said, the market in Japan is in transition And we are adapting to some of these transition by focusing on in force, focusing on driving the right product mix As well as driving a much more higher expense efficiency.
So I would just add that 5% Of our agent base in Japan is not a really significant number unlike in other markets where we have very significant agent count. In Japan, we have a smaller agency force and 5% isn't really a huge number of agents that would be in the normal course Of movement from quarter to quarter. But as Sunil highlights, our focus on agency across Asia has been strong and we've seen Significant increases, not just over the last few years, but certainly in the quarter on last year as well.
Thank you.
Thank you. The next question is from Gabriel Dechaine of National Bank Financial. Please go ahead.
Two questions. 1, has the 10 year drop affected the Transaction activity in the legacy book or potential thereof? And 2, more importantly, Can you give us a sense of the duration of the product you're selling in Asia? I know there's going to be some variability there, but trying to get a sense of What kind of amortization schedule we're going to be facing when these new business gains are transitioned to IFRS 17? Thanks.
Yes, I'll start. This is Naveed. In terms of the interest rates and potential transactions, We do stay closely connected to potential buyers, investment bankers, really have our finger on the pulse of the market. We were seeing certainly that pricing was previously improving as interest rates had gone up and yield opportunities had gone up. And we haven't really seen a big pullback yet.
So we do see a lot of activity in the market, a lot of capital continuing to take deals. And From our end, we're continuing to regularly test potential opportunities to transact, evaluate the bid ask spread for every block and you certainly will transact if it generates value.
Thanks.
Thank you.
And Gabe, it's Steve. It's Steve. I can touch on your second question. While we don't disclose product by product the duration, One thing I'd point you to in our embedded value disclosure is we do disclose there the emergence of our free surplus generation. And when we get to IFRS 17, one of the disclosures that are required is illustrating how that CSM will amortize over time.
So in the meantime, I direct you to the embedded value disclosure. We've got products that are shorter term. We've got products That are longer term, but I think the EV disclosure gives some indication of how it evolves now and then we'll provide that Information when we transition to IFRS 17.
Okay. We'll follow-up offline, I guess. Have a good summer.
Thank you. The next question is from Meny Grauman of Scotiabank. Please go ahead.
Hi, good morning. Another question on new business gains. We're seeing that it's a big driver of CorePS growth This quarter and for some time. I'm trying to think through what that means in an IFRS 17 world In terms of new business gains are amortized, if that impact is more muted in terms of the overall contribution to Core IPS, How what steps into the breach in terms of the SOE line to keep the growth going? Just wondering if you could help me kind of think through that from a growth from a core earnings growth perspective.
Hey, Meny. This is Phil. Thanks for the question. Andy, you're absolutely right that new business gains are treated differently on an IFRS 17 basis. So as we transition from IFRS 4, the current basis to IFRS 17, What you'll see is that the equivalents of new business gains are deferred as where a liability is established in the balance sheet as contractual service margin.
And so I think that will be a really important metric or movement in the contractual service margin will be a really important metric in terms of measuring growth. And while it's too early to be specific about the impact of IFRS 17 on our financials, and That's really because the guidance and interpretations do continue to evolve. What I can confidently say is that whether you're looking at IFRS 17 earnings or movements in CSM or a combination of the 2, I think the underlying growth power of our insurance businesses will be clear Under IFRS 17.
So in terms of sort of assessing the earnings growth power, is it going to be important to Kind of look at both like we're not just going to be able to look at core PLS growth, but we'll have to look at that underlying servicing margin as well. Is that Kind of what you're suggesting in terms of thinking about that issue?
Absolutely. I think both earnings And movement in CSM will be really important metrics to look at under IFRS 17.
Yes. I think you hit the nail on the head, Meny, CSM is going to
be a
key measure through which to assess insurance companies going forward under IFRS 17. And the growth of CSM will be a good leading indicator for future profitability as it obviously gets amortized. So I think you're on the right train as it Like the CSM and looking at growth as a key driver of value in the future. This is a topic that we're going to have to spend a lot more time Discussing with you all. So we're looking forward to that as we are able to provide much more clarity in the coming quarters.
Thanks, Mark.
Thank you. The next question is from Lamar Persad of Cormark Securities. Please go ahead.
Yes, thanks. My question
is on the core EBITDA margin improvement in Wealth Management. So certainly, I think it's possible for the Core EBITDA margin to move higher, but my question is more so on the sustainability of the rate of improvement. So Could you really could you talk to me about what's the outlook for the core EBITDA margin improvement over time? Like usually when I think of these businesses and margin Improvements, I think of it as being a little bit more gradual, but we're seeing quite the step up so far this year. Thanks.
Yes, thanks for
the question, Lamar. It's Paul here. Yes, as you mentioned in terms of the EBITDA margin, we have seen a pretty big pickup over the last year and We're now 4 consecutive quarters being above 30, which was our previous guidance of trying to get to that, Mark, which Just obviously a new threshold we've surpassed and feeling quite comfortable where we are. What I would say is, as we've highlighted previously, we try and target Bench growth is about half of revenue growth in the G WAN business, but you do need to look at this over a longer term time frame. We will need to invest in the business.
Expenses We'll move around a little bit quarter to quarter. So it's not going to be straight trajectory on the way up. We're going to have to invest and a lot of it is dependent on markets. What we're focused on is what we can control. And I think as you look at our franchise and the diversification and frankly the strategic choices we have by region where margins Our different particularly in Asia and Canada and by channel.
We just put the strength of our retail franchise again where we tend to see higher margins. We're feeling really good just about our ability to consistently deliver positive net flows over the long term And our ability to drive efficiencies out of the global franchise. One of our milestones this quarter is we surpassed $1,000,000,000,000 in assets under management and administration for total GUM. That gives us tremendous scale for the business. So we do believe we can continue to drive margin improvement as we go forward, but That's going to be dependent on market levels, mix of business, investor preferences, etcetera.
But overall, I would say fundamentals of the business are good. We feel we can continue to drive this margin higher over the long term.
So, Mara, I would just add as well. I would highlight that this was our 4th Straight quarter where our core EBITDA margin was greater than 30%. That was a huge milestone for us to continue to demonstrate success In growing our core EBITDA margin and we've consistently done that notwithstanding Paul's comments that we are going to see some variability. 2 big factors that are helping us Our a, our global scale, which is really coming to the fore when you're able to defray or leverage your expense base across multiple markets, that's certainly an advantage For us on margin, the second as Paul highlighted is that we have tremendous growth opportunities in geographies, which have very high margins. And whilst we may see some competitive pressures on fees in certain geographies, the fact that we're growing in other geographies That are higher margin is certainly a tailwind for us and something that we're very excited about, which is why at Investor Day we highlighted that Global WAM Was a key opportunity for us as we look forward to not just the next couple of years, but quite frankly, the next decade.
Great. Thank you. And then my second question is on expenses.
So it's maybe more appropriate for Phil. So far in 20 21, the efficiency ratio has been meaningfully below your less than 50% target. What this seems to suggest to me is 1 of 2 things, either we're likely to see the target move down to something lower or a higher mix ratio. So Can you talk to me about which of those 2 are more likely in your view? And if a higher mix ratio is more likely, what's going to drive that?
Thank you.
Hey, Lamar. Thanks for the question. And your observation is absolutely right. We've been notably below the 50% Benchmark the target that we've set ourselves for 2022 and that it's been below it for a couple of quarters now. What I would highlight though is that when we talk about a 50% cost efficiency ratio.
We're looking at consistently delivering that over a period of time. And there always is some seasonality with expenses. And I'm not yet satisfied that we are consistently delivering An efficiency ratio below 50%. So that's something that I think we need to observe over a number of more quarters. There is a tailwind at the moment in that pretax core earnings has been growing very strongly in the first half of the year and that is favorable for the efficiency ratio.
But I want to emphasize from an expense management perspective, Our priority here is very much strategic expense management, strategic cost management. So it's not about belt tightening. Our program is mature and we're looking to link efficiency with other elements of our strategy, in particular the digital and customer Elements of our strategy and our ability to deliver scalable growth. And this touches on your earlier question to Paul. There's a real link between our ability to scale the organization and our efficiency program, because we're then able to grow the business in an efficient manner, which is why both on the insurance side and on the Wealth and Asset Management side, you see that operating leverage emerge.
You touched on the future and one of the things that I commented on at Investor Day is what happens beyond Beyond consistently delivering a 50% cost efficiency ratio and what we said there is that We really target to deliver positive jaws, which means we expect the growth in our pretax, pre expenses core earnings To outpace the growth in our expenses. And I think that does speak to ongoing operating leverage that would take the ratio below 50% beyond 20 22.
All right. Thank you.
Thank you. The next question is from Nigel D'Souza From Veritas Investment Research, please go ahead.
Thank you. Good morning. I wanted to follow-up on U. S. Life experience in this quarter.
And with the emergence of the Delta variant, we're seeing COVID trends diverge on a state by state basis with some states Having more adverse experience, I was wondering if you could refresh us on your U. S. Life policyholder Mixed geographically, are there certain states that you're more concentrated in, in the U. S. Or less concentrated in?
And how do you expect that to translate into Claim experience on the Life side in the near term.
Thanks, Nigel, it's Steve. I can start and Mary Anne can add to her comments if she would like to as well. Reminder of some of what we saw during the pandemic last year Well, as we saw diversity in terms of our mortality and our longevity risk. So we saw while we saw losses on our mortality business In U. S.
Life, we saw gains in long term care. Now and those trends can deviate a little bit quarter to quarter, but the diversification My expectation is that we it's hard to predict how the variance evolve, But if we watch the trends right now, the rates of mortality have come down substantially. And I mentioned earlier The protection that the population over 65 has received, I think is a positive sign. So depending how this emerges, I would still expect to see offsets. I think it's just difficult to predict right now what the variance might do.
I don't know if Mary Anne wants to comment on geographic mix.
Yes, happy to Steve. Thank you. From a geographic mix, we are across the entire U. S, but we are concentrated definitely more so in the big States like California, in the past New York, Florida, New England states. We have actually stopped Selling in New York, any new business.
We still have some product offerings that are there, but we have pulled out of New York temporarily, but We are generally all across the U. S.
Okay. And that would apply for long term care as well. So I was just adding that that would apply for long term care as well. So the comment around the diversification benefit, I expect to continue to exist.
Okay, that makes sense. And if I could tie that together with your longer term strategy of reducing the contribution to core earnings from LTCNVA, tying your previous comments together, if we have variants that are more vaccine resistant or escape the vaccine and COVID-nineteen becomes more endemic instead of a pandemic. Can you explain or just try more color on how that fits with your long term strategy to reduce The LTC and VA exposure, wouldn't you want that longevity exposure offset to exist or to be substantial if Mortality risk is elevated in an endemic COVID-nineteen scenario. How do you think about it long term?
Sure. What we've seen through the pandemic is that while we've taken some losses On the mortality side, relative to a balance sheet position, they've not been that material. In terms of the overall mortality risk that the company has, quite comfortable with that. And the focus that we've got on optimizing legacy, We believe that that is a very desirable prudent approach to take even if We did end up with a little bit less diversification on the mortality side, but that we don't think that would be material for the company.
I'll just chime in and add. I think Steve answered the question correctly. The diversification has certainly helped us and we saw that not just in the last couple of quarters, but Quite frankly over the course of 2020. But the gross impacts on both sides of those equations aren't that significant in the scheme of things. And again, we see a lot of value in continuing to focus on reducing our legacy businesses.
And as we mentioned at Investor Day, LTC and VA We'll command much greater focus for us and that certainly isn't going to change.
Okay. Appreciate the color. Thank you.
Thank you. The next question is from Barco Mihalic of RBC Capital Markets. Please go ahead.
Hi, thank you. Good morning. I have three questions, but I'll adhere to the 2 question limit. The first question is an easy one, I think. In the U.
S, we had very good sales and very good new business gains. What I'm interested in knowing is what was the biggest driver Of the increase in the new business gains and how sustainable do you think this new level is?
Thanks, Deriko for the question. It's Mary Anne. Certainly, in the first half of twenty twenty one, we certainly benefited from higher customer demand really across all of our product lines and our new business growth rates continue to be quite strong. The new business gains specifically were a combination of our strong sales as well as favorable margins. And the margin increase, as you can imagine, with the strong sales, we get efficiencies of scale.
But it's also as a result of some of our continued discipline that we have in our pricing of our products, new product development, as well as significant Expense management that Phil was talking about earlier, which were all part of our strategic plan that we had set back in 2018. And so we've been really working on the profitability of the overall business. So So we're quite pleased with where we have landed. We also tend to play in the portions of the market that have the highest margins as well. And I do think that makes a difference.
And just a reminder that our high net worth international business that's run out of Bermuda is also part of our U. S. Segment as well and the margins on that business Are very, very high. And we do see a competitive advantage with Vitality. And as we continue to go forward, All of these factors together, we think the fundamentals are strong and there will be variability similar to what Anil was talking about In terms of gains, but I think we feel good about the future as well.
Okay. Thank you. And so Just to further emphasize, you think I mean, obviously, there's variability, but we've hit sort of like a new run rate level, give or take a few Give or take $10,000,000 or $20,000,000
Yes. I think that we're feeling pretty good about where we are, again, based on some variability. I Do you want to commit to a new run rate? Obviously, the sales growth was a significant factor to this. But on the margin side, we feel good about where the margins are And a lot of the work that we've done in order to get the profitability in a good spot.
Okay. Thank you very much for that. My second question is Probably for Steve, but may also include you, Mary Anne. So we were reading today about massive changes in Canada with respect to long term care, possibly resulting in significantly higher costs To run-in long term care homes in Canada, clearly a different paradigm in the U. S.
But I know next year you're going into The large assumption review. So the question is, is this something that's on your radar screen? How sensitive And how big of magnitude is there possibly for a change to expense Assumptions in the long term care blocks. And then an addendum to that is how quickly can you adjust premium rates based on significantly higher expenses for long term care. I realize there's a lot of parts to that question, But any kind of insight there would be interesting and helpful.
Thank you.
Thanks Darko. It's Steve. I can start and Mary Anne may wish to add. We're watching closely All the potential implications over time from the pandemic and that would include what the trends are In long term care, will there be a shift in care setting? Will more care be delivered at home?
What might the Cost of long term care services be? And the short answer is right now, we don't know. I think What we saw in the Q2 is customers are just starting to feel comfortable resuming care of some kind. But in terms of the longer term trends, we're going to have to study that really, really closely. In terms of how If we if there were trends that emerged, the question around adjusting premiums, that has been A lever that we have been able to use giving customers options, we disclosed at Investor Day that we've achieved $9,000,000,000 of premium increases over time and continue to make progress against our filings with the state.
So it has been a very effective lever. If there are clear Clearly defined trends, those are things that we can file for rate increases. So once there are very clear trends, we can And would take action. So Mary Anne, I'll pass to you if
you have anything to add.
Yes. I think you covered it very well, Steve. I really don't have anything Adding to
that. So just a quick follow-up on that, Steve. So the suspicion
that I have brewing is you'll do your work and you as a company may decide to get ahead of that expense curve And possibly results in a large reserve build. And then only afterwards, once there is clear evidence Of an increase in costs, can you go back and ask for premium rate increases? Is that a possible outcome here
Or a likely outcome? No. Let me be clear. On the reserving side, Given that we're talking about a long term exposure, I would not adjust reserves until there were Very, very clear trends. That's either positive or negative by the way.
So the reserving My expectation, the reserving would line up with we need to have confidence in the trends before we would change premiums. We need confidence in the trends before we change assumptions. And in Long Term Care, there are there's a variety of different things going on. As I mentioned, you talked about Potential for higher cost, I don't know if that will occur. I have not settled on that.
The other trends that Could be positive would be more Home Care, which tends to be less expensive. So I think we need to watch the trends and there won't be any knee jerk reactions.
Okay. That's very helpful. Thank you, Gene.
Thank you. The next question is from Paul Holden of CIBC. Please go ahead.
Thank you. Good morning. So first question is related to premium rate increases in long term care while we're on that topic. Seems like we've been waiting for some of those additional rate increases to come through. Are there any updates there?
This is, hi Paul, it's Naveed here. I'll take that question. So we're continuing to make progress at exceeding rate increases In line with our original expectation. We had recent favorable LTC policy experience, but we don't think that will be detrimental To our first, our rate increases, as you've laid out, are based on long term expectations and production and our long term expectations Haven't changed. We actually also haven't seen any material impact on responsiveness from the states on contractually permitted rate increases.
The pace of approval is actually stable overall and is consistent with the last few years. We continue to get approvals in Q2 and we're tracking well relative to our plans and what's embedded in our reserve. So on Investor Day, we announced that we received over $1,000,000,000 of the assumed $1,900,000,000 embedded in our padded Our reserves. And of the $6,000,000,000 that we have actual justification for and that we're still pursuing, So $5,000,000,000 still outstanding and that we're actively working on. And as Steve said, overall that's $9,000,000,000 of approval On the program to date, so really a track record of execution.
Okay, got it. Yes. Obviously, the reason I asked is it's a large number. So second question I had and coming back to Naveed, Part of your answer around VA again was you'll transact if it generates value for shareholders. And I think I tried to ask on the last conference call.
But again, I think it's important to set the table for everyone in terms of What is the correct lens for viewing creation of shareholder value on a VA transaction? Just so the day The press release comes out, everyone can kind of look at it and understand what lens we should be viewing it in terms of Shareholder value creation.
Yes. So I would say, I mean, the focus on any potential VA transaction is Risk reduction, such as the contingent capital risk on VA. And as you point out, transacting at a Price point, that's in the best interest of shareholders. I guess you're trying to get at how we determine that. Obviously, there's a lot of factors.
I mean, the risk reduction is a factor in that. We know that earnings on variable annuities are discounted. Different analysts do different some of the parts analysis and value of it in different ways, but we know there's a range there. And we look at that range, we look at what the pricing on a VA transaction would be in terms of capital release Versus that range of multiples and that's sort of how we determine whether transactions in the best Mr. Albers, along with obviously the risk reduction benefits.
And then maybe a follow-up on that one. Is it also fair to assume that You're going to free up some capital obviously with a VA transaction and therefore the potential redeployment of that capital also goes into that value equation, is that a fair assumption?
Yes, that's a fair assumption.
Okay. Thank you.
Thank you. The next question is from Mike Rysanovich of Credit Suisse. Please go ahead.
Hey, good morning. A question for Anil. I want to go back to the Asia business. And just looking at the 20% growth rate that you've talked about year over year basis. And you had a pretty big sequential step function up in Q3 of 2020.
So It looks like you're coming up against a very tough comp year over year next quarter. So I'm just wondering what is it that changes in the business In the near term, that's going to get you there and keep you on that 15% plus targeted growth rate. Because when I do look at the last four quarters, you haven't really had much movement even on a CER basis in terms of your core ROE in U. S. Dollars.
Thanks for the question. So in terms of the way we can Think about the business is through a lens of how we're faring on our drivers. And towards that, I had emphasized the fact that we continue to expand our distribution. We now have 117,000 agents In Asia, we have 10 exclusive bank partnerships. And across both the agency growth as well as penetrating Further, our bank partner base, we have significant opportunity to be able to drive momentum on an ongoing basis.
I also do want to kind of highlight the fact that we have made significant investments and continue to do so in improving our digital experience and Specifically, when it comes to how distributors interact with our customers. And that has a couple of knock on impacts. 1, It allows us greater expense efficiency, but also it allows us greater productivity and a higher customer experience on account of the investments that we are making on digitization. One of the other points that we've illustrated in the past and Roy alluded to that as well, one of the key strengths Within our Asia franchise is the diversity of our operation. And from time to time, you would have noticed that If we do face a headwind in one market, it does kind of then get compensated by a tailwind in the other.
And that is something that We would continue to kind of amplify as we kind of think about all our reported segments going forward. So In the short term, we might have some momentum challenges on account of the resurgence of COVID, and that's something that I mentioned earlier as well, Typically impacting our Southeast Asian markets like Vietnam, Philippines, Indonesia, Malaysia, they have kind of seen a significant increase in COVID. But as I said, we've also gained experience over the last 18 months to operate in a COVID environment. So we're watching that very closely. But from a medium to longer term perspective, just the secular trends in Asia, given our significant market positions In many of the geographies that we operate in as well as our ongoing investments in driving momentum and digitization, we feel pretty good about capturing the growth opportunity in Asia.
Okay. Thanks for that. And then so you would expect most of that growth to Come into the expected profit line going forward, correct?
I would not I would say on both, right? We've kind of and I again mentioned that We have been applying specific emphasis on in force and you can see the robust growth that we have enabled to deliver in quarter 2, 16% in quarter 2 of this year, but you would also have to combine that with new business gain momentum as well, Which as you know is going to be highly correlated to new business sales volumes as I alluded earlier as well. And that's where the importance on Showing that the distribution is kind of lined up, your growth drivers are kind of pretty much in order It's going to be a key emphasis for us. So I guess it's going to be both across EPIS as well as new business care.
Okay. Thanks for that. And then just one quick one, maybe best for Phil. Just wanted to ask about the 328,000,000 New business gains, which is, of course, a net number. Can you provide any color on how much Strain there might be in that number.
I'm trying to get a sense of what the actual new business gains were on a gross basis, Which would be reduced by any negative strain. Do you have negative strain in some products that you sell and positive in others? What would both be the mix more broadly?
Thanks Mike for the question. This is Phil. So the $328,000,000 new business But that is a net number. That does include certain products that generate strain. I don't have the specifics in front of me of how much Sure.
The strain is embedded within that. Steve, I don't know whether you have any additional comment to make there.
Thanks, Phil. I don't have the numbers in front of me, but as you can imagine, we Given that you it's a drag on earnings and we do focus on where we see A strain coming through. We're constantly focused on looking at how we can improve profitability, etcetera. So where we do have it, it
So is it fair to assume that it's
a small number, the strain portion would be a small number To get to that net $328,000,000
That's Mike, certainly smaller than
Sorry,
Steve, go ahead.
Certainly smaller than the gross number, but I don't want certainly smaller than the gross number, but like I said, I don't have that Andy, we could follow-up with you, but I think that's
that's it.
Yes, maybe we can follow-up. Thanks very much for the color. Appreciate it.
Thanks, Mike.
Thank you. There are no further questions registered at this time. I would now like to turn the meeting over to Mr. Cao.
Thank you, operator. We will be available after the call if there are any follow-up questions. Have a nice morning everyone.
Thank you. The conference is now ended. Please disconnect your lines at this time and we thank you for your participation.